JFL Life

When is the next results date for JFL Life?

No Upcoming Board Meetings

What is the bonus history of the JFL Life?

JFL Life recently announced a 2:1 bonus issue, where shareholders will receive two additional shares for every one share held as of the record date on September 24, 2024. The ex-date for this bonus is also September 24, 2024.

JFL Life has a recent bonus history where they announced a 2:1 bonus issue. The ex-date for this bonus is set for September 24, 2024. This means that shareholders will receive two additional shares for every one share they hold as of the record date, which is also September 24, 2024.

Has JFL Life declared dividend?

JFL Life Sciences Ltd has declared a 2% dividend, amounting to 0.20 per share, with an ex-date of September 13, 2024. Despite the dividend, the company has experienced significant declines in price returns over various periods, resulting in negative total returns.

JFL Life Sciences Ltd has declared a 2% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2%<BR>- Amount per share: 0.20<BR>- Ex-date: 13 Sep 2024<BR><BR>Dividend Yield: 0.34%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -40.45%, the dividend return was 0%, resulting in a total return of -40.45%.<BR><BR>For the 1-year period, the price return was -46.96%, the dividend return was 0.50%, leading to a total return of -46.46%.<BR><BR>Over the 2-year period, the price return was -51.78%, the dividend return was 0.52%, culminating in a total return of -51.26%.<BR><BR>In the 3-year period, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>For the 4-year period, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>In the 5-year period, the price return was 0%, the dividend return was 0%, culminating in a total return of 0.0%.<BR><BR>Overall, while JFL Life has declared a dividend, the total returns over various periods indicate significant declines in price returns, with minimal contributions from dividends. This suggests a challenging performance environment for the company.

Is JFL Life overvalued or undervalued?

As of May 20, 2025, JFL Life is considered undervalued with a PE ratio of 15.59 and an EV to EBITDA of 8.61, showing significant improvement and potential for recovery despite a year-to-date decline of 39.02% compared to the Sensex's 6.24%.

As of 20 May 2025, JFL Life has moved from a grade of does not qualify to very attractive, indicating a significant improvement in its valuation outlook. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 15.59, an EV to EBITDA of 8.61, and a ROCE of 17.46%. <BR><BR>In comparison to its peers, JFL Life stands out with a much lower PE ratio than Sun Pharmaceutical Industries Ltd. at 35.25 and Divi's Laboratories Ltd. at 79.33, both of which are classified as expensive. The valuation metrics suggest that JFL Life is positioned favorably within the pharmaceuticals and biotechnology sector. Despite recent underperformance relative to the Sensex, with a year-to-date decline of 39.02% compared to the Sensex's 6.24%, the current valuation indicates a potential for recovery and growth.

What is the technical trend for JFL Life?

As of May 21, 2025, JFL Life's technical trend is mildly bearish, supported by negative signals from daily moving averages, Bollinger Bands, and KST, despite a mildly bullish weekly MACD.

As of 21 May 2025, the technical trend for JFL Life has changed from sideways to mildly bearish. The weekly MACD indicates a mildly bullish stance, but the monthly MACD is mildly bearish, suggesting mixed signals. The moving averages on the daily chart are also mildly bearish, reinforcing the negative outlook. Bollinger Bands and KST on the weekly are both bearish, while the Dow Theory shows a bearish trend on the weekly timeframe. The OBV is mildly bearish, indicating selling pressure. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the bearish indicators from Bollinger Bands and KST.

Who are the peers of the JFL Life?

JFL Life's peers include Lasa Supergeneri, Medicamen Organ., Transchem, Sandu Pharma, Shelter Pharma, Kabra Drugs, Medi Caps, Roopa Industries, Dipna Pharmachem, and Chandra Bhagat. JFL Life has average management risk, good growth, and an average capital structure, but its 1-year return of -71.12% is among the lowest in its peer group.

Peers: The peers of JFL Life are Lasa Supergeneri, Medicamen Organ., Transchem, Sandu Pharma., Shelter Pharma, Kabra Drugs, Medi Caps, Roopa Industries, Dipna Pharmachem, and Chandra Bhagat.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shelter Pharma, while Average management risk is found at JFL Life, Medicamen Organ., Transchem, and Medi Caps, and Below Average management risk is noted at Lasa Supergeneri, Sandu Pharma., Roopa Industries, Dipna Pharmachem, and Chandra Bhagat. Growth is Excellent at Medicamen Organ. and Good at JFL Life, Shelter Pharma, and Roopa Industries, while Below Average growth is seen at Lasa Supergeneri, Transchem, Medi Caps, and Sandu Pharma., and the rest have varying qualifications. Average capital structure is present at JFL Life, Lasa Supergeneri, Medicamen Organ., Transchem, and Medi Caps, while Good capital structure is noted at Sandu Pharma. and Roopa Industries, and Excellent capital structure is seen at Shelter Pharma, with Kabra Drugs not qualifying.<BR><BR>Return Snapshot: Medicamen Organ. has the highest 1-year return at -63.92%, while JFL Life has the lowest at -71.12%, indicating a worse performance compared to its peers. Additionally, Lasa Supergeneri, JFL Life, Medicamen Organ., and the rest have negative six-month returns.

Who are in the management team of JFL Life?

As of March 2022, the management team of JFL Life includes Smiral Ashwinkumar Patel (Managing Director), Manishkumar Jasvantlal Patel (Chairman & Non-Executive Director), Tejal Smiral Patel (Whole-time Director), Sonu Lalitkumar Jain and Bhavna Shah (Non-Executive & Independent Directors), and Pratima Singh (Company Secretary). These members are responsible for the company's governance and management.

As of March 2022, the management team of JFL Life includes:<BR><BR>1. Smiral Ashwinkumar Patel - Managing Director<BR>2. Manishkumar Jasvantlal Patel - Chairman & Non Executive Director<BR>3. Tejal Smiral Patel - Whole-time Director<BR>4. Sonu Lalitkumar Jain - Non-Executive & Independent Director<BR>5. Bhavna Shah - Non-Executive & Independent Director<BR>6. Pratima Singh - Company Secretary<BR><BR>These individuals play key roles in the governance and management of the company.

What does JFL Life do?

JFL Life Sciences Ltd is a Micro Cap pharmaceutical company that manufactures and markets products, with a recent quarterly net sales of 117 Cr and a net profit of 1 Cr as of March 2025. The company transitioned to a public entity in 2022 and has a market cap of INR 51 Cr.

Overview:<BR>JFL Life Sciences Ltd is a company that manufactures and markets pharmaceutical products, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Micro Cap.<BR><BR>History:<BR>JFL Life Sciences Ltd was incorporated as 'JFL Life Sciences Private Limited' in 2010. It transitioned from a Private Limited to a Public Limited Company on February 10, 2022, and subsequently changed its name to 'JFL Life Sciences Limited' on March 3, 2022. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 117 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 51 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 12.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.43% <BR>Debt-Equity: 0.16 <BR>Return on Equity: 11.69% <BR>Price to Book: 1.45 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the top shareholders of the JFL Life?

The top shareholder of JFL Life is Smiral Ashwinkumar Patel, holding 44.33% of the shares. The highest public shareholder is Pratik Rajendra Gandhi at 1.22%, while individual investors collectively own 28.99%.

The top shareholders of JFL Life primarily include the promoters, with Smiral Ashwinkumar Patel holding the largest share at 44.33%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Pratik Rajendra Gandhi, who owns 1.22%. Additionally, individual investors collectively hold 28.99% of the shares.

How big is JFL Life?

As of 24th July, JFL Life Sciences Ltd has a market capitalization of 51.00 Cr, with Net Sales of 54.68 Cr and a Net Profit of 2.01 Cr for the latest four quarters. Shareholder's Funds are 35.58 Cr and Total Assets are valued at 56.52 Cr as of March 2024.

As of 24th July, JFL Life Sciences Ltd has a market capitalization of 51.00 Cr, categorizing it as a Micro Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 54.68 Cr and a Net Profit of 2.01 Cr. This indicates a modest performance in terms of sales and a small profit figure.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 35.58 Cr and Total Assets valued at 56.52 Cr. This provides a snapshot of the company's financial standing at that time.

How has been the historical performance of JFL Life?

JFL Life has shown significant growth in net sales and profitability, with net sales increasing from 30.17 Cr in Mar'20 to 82.04 Cr in Mar'25, and profit after tax rising from 0.36 Cr to 4.16 Cr during the same period. However, cash flow from operations has been volatile, turning negative at -3.00 Cr in Mar'25.

Answer:<BR>The historical performance of JFL Life shows a significant growth trend in net sales and profitability over the past few years.<BR><BR>Breakdown:<BR>JFL Life's net sales have increased from 30.17 Cr in Mar'20 to 82.04 Cr in Mar'25, indicating a robust growth trajectory. Total operating income has followed a similar pattern, rising from 30.17 Cr to 82.04 Cr during the same period. The company's total expenditure, excluding depreciation, has also grown, reaching 73.85 Cr in Mar'25 from 28.31 Cr in Mar'20. Operating profit, which reflects the company's operational efficiency, has improved from 1.86 Cr in Mar'20 to 8.20 Cr in Mar'25, while profit before tax has increased from 0.50 Cr to 6.14 Cr in the same timeframe. Profit after tax has also seen a rise from 0.36 Cr in Mar'20 to 4.16 Cr in Mar'25. The company's earnings per share (EPS) have fluctuated, peaking at 10.8 in Mar'21 before settling at 1.26 in Mar'25. On the balance sheet, total assets have grown from 48.26 Cr in Mar'22 to 71.91 Cr in Mar'25, with total liabilities also increasing from 48.26 Cr to 71.91 Cr. The cash flow from operating activities has been negative in Mar'25 at -3.00 Cr, contrasting with a positive cash flow of 8.00 Cr in Mar'24. Overall, JFL Life has demonstrated significant growth in sales and profitability, although cash flow from operations has shown volatility.

How has been the historical performance of JFL Life?

JFL Life has shown significant growth in net sales and profitability, with net sales increasing from 30.17 Cr in Mar'20 to 82.04 Cr in Mar'25, and profit after tax rising from 0.36 Cr to 4.16 Cr during the same period, despite some cash flow challenges. Total assets and liabilities also grew, reflecting the company's expanding operations.

Answer:<BR>The historical performance of JFL Life shows a significant upward trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>JFL Life's net sales have increased from 30.17 Cr in Mar'20 to 82.04 Cr in Mar'25, reflecting a strong growth trajectory. Total operating income followed a similar pattern, rising from 30.17 Cr in Mar'20 to 82.04 Cr in Mar'25. The raw material costs also rose, from 26.72 Cr in Mar'20 to 66.77 Cr in Mar'25, indicating increased production expenses. Operating profit, excluding other income, improved from 1.86 Cr in Mar'20 to 8.19 Cr in Mar'25, while profit before tax increased from 0.50 Cr to 6.14 Cr in the same period. Profit after tax also saw a rise from 0.36 Cr in Mar'20 to 4.16 Cr in Mar'25. The company's total assets grew from 48.26 Cr in Mar'22 to 71.91 Cr in Mar'25, with total liabilities increasing from 48.26 Cr to 71.91 Cr. Cash flow from operating activities showed fluctuations, with a negative cash flow of -3.00 Cr in Mar'25, contrasting with a positive cash flow of 8.00 Cr in Mar'24. Overall, JFL Life has demonstrated robust growth in sales and profitability, despite some challenges in cash flow management.

Should I buy, sell or hold JFL Life Sciences Ltd?

Why is JFL Life Sciences Ltd falling/rising?

As of 28-Jan, JFL Life Sciences Ltd's stock price remains at 10.00, reflecting a 0.00% change, with a significant decline of 58.16% over the past year. Despite a strong ability to service debt, disappointing financial results and low trading activity contribute to the stock's bearish trend.

As of 28-Jan, JFL Life Sciences Ltd is experiencing a decline in its stock price. The current price remains unchanged at 10.00, reflecting a 0.00% change. Over the past week, the stock has underperformed, showing a decrease of 2.91%, while the benchmark Sensex has increased by 0.74%. In the last month, the stock has fallen by 24.81%, compared to a slight decline of 2.69% in the Sensex.<BR><BR>Year-to-date, JFL Life Sciences Ltd has seen a drop of 20.00%, and over the past year, the stock has plummeted by 58.16%, contrasting sharply with the Sensex's gain of 10.39%. The three-year performance is similarly concerning, with a decline of 72.97% against a 43.96% increase in the benchmark.<BR><BR>Today's performance indicates that the stock has underperformed its sector by 0.48%. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which suggests a bearish trend. Although there has been a slight increase in investor participation, with delivery volume rising by 7.14% on January 23, the overall liquidity remains low, indicating limited trading activity.<BR><BR>Financially, the company has shown a strong ability to service its debt, with a low Debt to EBITDA ratio of 1.22 times, and its operating profit has grown at an annual rate of 34.76%. However, the recent financial results have been disappointing, with net sales for the first nine months showing a decline of 24.76% and a significant drop in profit after tax by 38.46%. These factors contribute to the stock's negative performance and suggest that investors are cautious, leading to the stock's current decline.

Which are the latest news on JFL Life?

Are JFL Life Sciences Ltd latest results good or bad?

JFL Life Sciences Ltd's latest results show a significant quarter-over-quarter sales increase of 158.07%, but a 24.30% decline year-over-year, alongside reduced operating margins and ongoing profitability challenges, indicating a mixed and concerning financial outlook.

JFL Life Sciences Ltd's latest results present a mixed picture, reflecting significant volatility in its financial performance. On one hand, the company reported a remarkable 158.07% increase in net sales quarter-over-quarter, reaching ₹29.91 crores. However, this figure is still down 24.30% compared to the same quarter last year, indicating a challenging year-over-year performance.<BR><BR>The operating margin has contracted to 9.76%, down from 16.65% in the previous quarter, which raises concerns about the company's pricing power and cost management. While net profit saw a substantial increase of 162.67% QoQ to ₹1.97 crores, it remains 35.86% lower than the prior year, highlighting ongoing profitability challenges.<BR><BR>Additionally, the nine-month performance for FY26 shows a decline in sales by 24.76% and a 38.46% drop in profit after tax compared to the same period last year. This suggests that the recent quarterly uptick may not be sustainable and raises questions about the overall health of the business.<BR><BR>Furthermore, the absence of institutional investors and the company's reliance on sporadic bulk orders rather than steady revenue streams contribute to a perception of instability. Overall, while there are some positive indicators in the latest results, the underlying issues and volatility suggest that the company's performance is more concerning than reassuring at this time.